Sept. 04, 2025 — CorVista Health has published a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System, a non-invasive, point-of-care diagnostic test for pulmonary hypertension (PH).

Sept. 9, 2025 — Neurescue ApS has received CE Mark approval for its Neurescue device, a medical device approved to treat non-shockable cardiac arrest. Granted by TÜV SÜD after an expedited six-month review under Europe’s Medical Device Regulation (MDR), this milestone marks one of the most significant advances in resuscitation since the introduction of CPR in 1960.

Sept. 8, 2025 — GE HealthCare recently announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group that provides end-to-end cardiac positron emission tomography (PET) imaging solutions to hospitals and outpatient practices throughout the U.S.

Sept. 8, 2025 — Pulse Biosciences, Inc., a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) technology, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to proceed with the initiation of its nsPFA Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation (AF).

Sept. 8, 2025  — AMO Pharma Ltd., a clinical-stage specialty biopharmaceutical company focusing on rare genetic disorders with limited or no treatment options, has announced a license agreement with Population Health Research Institute (PHRI), a joint global health research institute of McMaster University and Hamilton Health Sciences, and Venca Research Inc. The agreement will support the development and potential manufacturing, and commercialization of AMO-02 in arrhythmogenic right ventricular cardiomyopathy (ARVC).

Sept. 5, 2025 — Idorsia Ltd has announced a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes and worsening outcomes.

Sept. 4, 2025 —  Royal Philips has introduced a new telemetry platform designed to help address critical challenges in healthcare — including staff shortages and alarm management. A key component of the solution is the next-generation Telemetry Monitor 5500 which offers a comprehensive, data-driven approach to operational performance and patient care for cardiac monitoring. 

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular disease prediction and prevention. The company will shape the future of cardiovascular health by empowering individuals to understand and reduce their risk of atherosclerotic cardiovascular disease (ASCVD). With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives. 

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure substudy of SECURE, evaluating the Varipulse Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF).

Sept. 2, 2025 — Stereotaxis has announced the successful completion of the world’s first procedures using MAGiC Sweep, a robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now